摘要
为评价蒙药组方对慢性阻塞性肺疾病(慢阻肺)疗效,招募稳定期患者153例,94例给予布地奈德福莫特罗或茚达特罗格隆溴铵(西药组),59例给予加味阿嘎日、赞丹-20、清肺润泽丸等(蒙药组)。治疗3个月,蒙、西药组肺功能和6 min步行试验(6MWT)结果无显著差异;圣乔治呼吸问卷(SQGR)症状评分组间差异显著(校正后P=0.021)。与基线相比,蒙药组慢阻肺评估测试(CAT)评分下降6分,显著高于西药组(校正后P<0.001);CAT评分下降2分及以上比例与降低或不变比例显著高于西药组(P_(△CAT)≤-2=0.001,校正后_(P降低/不变)=0.035);蒙药组SQGR疾病影响评分降低11.19分,西药组降低6.98分,蒙药组的下降值显著高于西药组(P=0.014)。证实了蒙药组方可显著缓解慢阻肺稳定期患者呼吸道症状,改善心肺功能。
To evaluate the therapeutic effect of Mongolian traditional prescriptions on patients with chronic obstructive pulmonary disease(COPD),a total of 153 COPD patients at stable stage were recruited,among which 94 patients were treated with budesonide,formoterol or indacaterol(western medicine group),and 59 patients were given additional Agari,Zandan-20,Qingfeirunze pill,etc.(Mongolian medicine group).After three months treatment,there was no significant difference in the pulmonary function indexes or six-minute walk test(6MWT)results between Mongolian and western medicine groups.There were significant differences in symptom score of Saint George's respiratory questionnaire(SGRQ)between the two groups(Adjusted P=0.021).Compared with the baseline,the chronic obstructive pulmonary disease assessment test(CAT)score of the Mongolian medicine group decreased by 6 points,which was significantly higher than that of the western medicine group(Adjusted P<0.001).For the CAT score,the proportions of patients decreased by 2 points or more,and the ratio of treated patients with lower or constant CAT score in the Mongolian medicine group were significantly higher than those in the western medicine group(P_(△CAT)≤-2=0.001,corrected P_(decreased/fixed number)=0.035).The disease impact score of SQGR decreased by 11.19 points in the Mongolian medicine group and 6.98 points in the western medicine group.The score of the Mongolian medicine group was significantly higher than that in the western medicine group(P=0.014).It was confirmed that the Mongolian medicine combined prescription can significantly improve respiratory symptoms,elevating the cardiopulmonary function.
作者
孙德俊
布仁巴图
刘晓玲
那仁满都拉
刘慧招
金桃
李媛
梁丹艳
高笑宇
SUN Dejun;Burenbatu;LIU Xiaoling;Narenmandula;LIU Huizhao;JIN Tao;LI Yuan;LIANG Danyan;GAO Xiaoyu(Key Laboratory of National Health Commission for the Diagnosis&Treatment of COPD,Inner Mongolia Key Laboratory of Respiratory Diseases,Inner Mongolia People's Hospital,Hohhot 010017,China;Affiliated Hospital of Inner Mongolia University for Nationalities,Tongliao 028000,China)
出处
《科技导报》
CAS
CSCD
北大核心
2022年第23期58-65,共8页
Science & Technology Review
基金
中国医学科学院中央级公益性质科研院所基本科研业务费专项(2019PT350001)
国家重点研发课题(2018YFC1708002)
内蒙古自治区科技计划项目(内财科[2022]662号)
国家自然科学基金地区项目(81960013)
中央引导地方科技发展资金项目(ZYZ20200486)
内蒙古自治区人民医院博士启动金项目(2019BS08)。
关键词
慢性阻塞性肺疾病
蒙药
加味阿嘎日
赞丹-20
清肺润泽丸
6
min步行试验
肺功能
呼吸量表
chronic obstructive pulmonary disease(COPD)
Mongolian medicine
additional Agari
Zandan-20
Qingfeirunze pill
six-minute walk test
pulmonary function
respiratory scale
